Avalon GloboCare Corp. AVCO
At closeNov 10, 2022, 12:00 AM EST
- Market cap
- 52.18M
- Revenue (ttm)
- 1.36M
- EPS (ttm)
- -0.102
- Shares out
- 99.22M
- P/E ratio
- -5.16
- Volume
- 432.17K
- Avg volume
- 182.99K
- Open
- 0.62
- Previous close
- 0.5259
- Day's range
- 0.5202 – 0.6507
- 52-week range
- 0.38 – 1.07
- Beta
- 0.81
Key statistics
- Enterprise value
- 46.47M
- PEG ratio
- 0.00
- Price / sales
- 38.42
- Price / book
- 262.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 5.30%
- Free cash flow
- 1.35M
- Total cash
- 1.18M
- Total debt
- 3.01M
- Return on equity
- -497.06%
- Short % of float
- 1.05%
- 50-day average
- 0.51172
- 200-day average
- 0.592295
Next earnings
Consensus EPS estimate 0.00.
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
- Sector
- Real Estate
- Industry
- Real Estate Services
- Country
- United States
- Website
- avalon-globocare.com
News
Avalon GloboCare to continue US-centric strategy with new proposed board composition ahead of Laboratory Services MSO acquisition 
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday 
Avalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31M 
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday 
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday 
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now 
Avalon GloboCare gets notice of allowance from US patent office for QTY fusion platform 
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday 
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session 
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Your note
Sign in to keep a note on AVCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LU WENZHAO | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Aug 4, 2022 | 35,837,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 0.70% | 516,992 | 271.89K | Jun 29, 2022 |
| Geode Capital Management, LLC | 0.20% | 147,623 | 77.63K | Jun 29, 2022 |
| Northern Trust Corporation | 0.06% | 47,277 | 24.86K | Jun 29, 2022 |
| Virtu Financial LLC | 0.05% | 34,062 | 17.91K | Sep 29, 2022 |
| Ground Swell Capital, LLC | 0.04% | 28,808 | 15.15K | Jun 29, 2022 |
| Blackrock Inc. | 0.04% | 28,676 | 15.08K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.68% | 503,819 | 264.96K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.11% | 78,171 | 41.11K | Aug 30, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 48,932 | 25.73K | Aug 30, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.03% | 25,483 | 13.40K | Sep 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.02% | 12,514 | 6.58K | Aug 30, 2022 |